MARKET

ARWR

ARWR

Arrowhead Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.78
-1.32
-3.06%
Opening 12:50 09/21 EDT
OPEN
41.67
PREV CLOSE
43.10
HIGH
43.56
LOW
41.30
VOLUME
590.58K
TURNOVER
--
52 WEEK HIGH
73.72
52 WEEK LOW
19.51
MARKET CAP
4.27B
P/E (TTM)
-173.7937
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ARWR: Better Than Anticipated Interim Data for ARO-AAT…
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Positive Interim Data for ARO-AAT On September 16, 2020, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced interim 24-week biopsy data for four patients from AROAAT2002, an open label Phase 2 clinical trial of ARO-AAT
Zacks Small Cap Research · 7h ago
Arrowhead Hits the Bullseye in Phase 2 Study of ARO-AAT; Analyst Targets Over 90% Upside
Wednesday was a good day for investors of biotech Arrowhead Pharmaceuticals (ARWR). Shares took off to the tune of 40% following the release of positive trial data.In the Phase 2 open-label trial (AROAAT2002) assessing ARO-AAT for the rare genetic liver disease associated with alpha one antitrypsin deficiency
TipRanks · 3d ago
Mid-Afternoon Market Update: Dow Jumps 300 Points; Fed Leaves Interest Rates Unchanged
Toward the end of trading Wednesday, the Dow traded up 1.1% to 28302.78 while the NASDAQ rose 0.06% to 11196.87. The S&P also rose, gaining 0.63% to 3,422.61.
Benzinga · 4d ago
Arrowhead Pharma Reveals Positive Data On Drug To Treat Liver Disease; ARWR Stock Jumps
Investor's Business Daily · 4d ago
Why Arrowhead Pharma's Stock Is Trading Higher Today
Arrowhead Pharmaceuticals (NASDAQ: ARWR) shares are trading higher on Wednesday after the company announced positive interim 24-week liver biopsy results in four subjects from AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company's second-generation investigational RNA interference
Benzinga · 5d ago
Mid-Day Market Update: Crude Oil Surges 4%; Eastman Kodak Shares Spike Higher
Midway through trading Wednesday, the Dow traded up 0.77% to 28,207.22 while the NASDAQ fell 0.05% to 11,184.63. The S&P also rose, gaining 0.43% to 3,415.98.
Benzinga · 5d ago
Looking Into Arrowhead Pharmaceuticals's Return On Capital Employed
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported Q3 sales of $27.38 million. Earnings fell to a loss of $15.95 million, resulting in a 28.3% decrease from last quarter. Arrowhead Pharmaceuticals collected $23.53 million in revenue during Q2, but reported earnings showed a $22.24 million loss.What Is
Benzinga · 5d ago
Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losers
Gainers: Arrowhead Pharmaceuticals (ARWR) +46%, Myomo (MYO) +38%, AxoGen (AXGN) +15%, Covetrus (CVET) +14%, Inovio Pharmaceuticals (INO) +13%.Losers: Novus Therapeutics (NVUS) -13%, Jounce Therapeutics (JNCE) -10%, Syneos Health (SYNH) -7%, Verastem (VSTM) -5%, Evogene (EVGN) -5%.
Seekingalpha · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARWR stock price target is 64.45 with a high estimate of 90.00 and a low estimate of 31.00.
EPS
Institutional Holdings
Institutions: 396
Institutional Holdings: 78.51M
% Owned: 76.75%
Shares Outstanding: 102.29M
TypeInstitutionsShares
Increased
95
4.01M
New
74
1.37M
Decreased
75
2.92M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.60%
Pharmaceuticals & Medical Research
-3.26%
Key Executives
Chairman/Director
Douglass Given
Chief Executive Officer/President/Director
Christopher Anzalone
Chief Financial Officer
Kenneth Myszkowski
Chief Scientific Officer
Curt Bradshaw
General Counsel
Patrick O'Brien
Other
James Hassard
Other
Javier San Martin
Lead Director/Independent Director
Michael Perry
Independent Director
Marianne De Backer
Independent Director
Mauro Ferrari
Independent Director
Oye Olukotun
Independent Director
William Waddill
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average ARWR stock price target is 64.45 with a high estimate of 90.00 and a low estimate of 31.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ARWR
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Arrowhead Pharmaceuticals Inc stock information, including NASDAQ:ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.